Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: Identification of a robust signature for clinical outcomes and immunotherapy response in gastric cancer: based on N6-methyladenosine related long noncoding RNAs

Fig. 6

Correlation of the risk score and ICB therapy response. a The correlation analysis of the m6A-related lncRNAs, risk score and clinical factors. b, c The differential expression analysis of two essential immune checkpoints (PD-1 and CTLA4) in low-risk and high-risk groups. d The relationship between risk score and response to immunotherapy. m6A-LPS, m6A-related lncRNA prognostic signature; ICB, immune checkpoint blocker

Back to article page